You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said the funding will support international expansion of its FebriDx rapid point-of-care test and its US clinical trial.
A number of firms internationally have announced development of molecular assays and reagents for the novel coronavirus 2019-nCoV.
The company announced Monday that it has inked a contract to become the primary supplier of products for immunoassay testing to Quest Diagnostics.
The partners aim to develop new diagnostic technologies and businesses, with a focus on diseases for which there are no established diagnostic methods.
China remains a key strategic market for Roche, and it said that it has multiple assays for 2019-nCoV coronavirus for research-use only.
The Chinese company has also granted the underwriters of the offering an option to purchase an additional 200,004 ADS to cover overallotments.
A subsidiary of Curetis, a firm recently merged with OpGen, Ares will use BGI technology to sequence samples in Europe.
The DNBSEQ-T7 ultra-high-throughput sequencer, metagenomic sequencing kit for coronaviruses, and 2019-nCoV RT-qPCR kit have received authorization from China's NMPA.
Uppsala University spinout Astrego has developed a system to rapidly detect bacterial infection and antibiotic susceptibility in biofluid.
OvaCis is a CE-IVD marked in vitro diagnostic that can be used to assess epithelial ovarian cysts.